• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Klotho Neurosciences Inc.

    7/2/25 3:40:15 PM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KLTO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    KLOTHO NEUROSCIENCES INC.

    (Name of Issuer)


    COMMON STOCK, $0.0001 PAR VALUE PER SHARE

    (Title of Class of Securities)


    49876K103

    (CUSIP Number)


    12/04/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    49876K103


    1Names of Reporting Persons

    Austria Capital LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,000,000.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,000,000.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,000,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox checked
    11Percent of class represented by amount in row (9)

    9.405 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  Note to 5, 7, 9 and 11: Based on 21,263,515 shares outstanding as of November 19, 2024 pursuant to a Form 10-Q filed on November 19, 2024 with the Securities and Exchange Commission for the quarter ended September 30, 2024. Note to 10: Excludes a Convertible Note which contains a contractually stipulated 4.99% ownership restriction. The full conversion of the Convertible Note by Austria Capital LLC would exceed this restriction.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    KLOTHO NEUROSCIENCES INC.
    (b)Address of issuer's principal executive offices:

    13576 Walnut Street, Suite A, Omaha, NE 68144
    Item 2. 
    (a)Name of person filing:

    Austria Capital LLC
    (b)Address or principal business office or, if none, residence:

    1818 51st Street, Brooklyn, NY 11204
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    COMMON STOCK, $0.0001 PAR VALUE PER SHARE
    (e)CUSIP No.:

    49876K103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2,000,000.00
    (b)Percent of class:

    9.405%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    2,000,000.00

     (ii) Shared power to vote or to direct the vote:

    0 Shares

     (iii) Sole power to dispose or to direct the disposition of:

    2,000,000.00

     (iv) Shared power to dispose or to direct the disposition of:

    0 Shares

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Austria Capital LLC
     
    Signature:/s/ Isaac Schreiber
    Name/Title:Isaac Schreiber, Sole Member
    Date:06/05/2025
    Get the next $KLTO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $KLTO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KLTO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity Rules

      Klotho Neurosciences Maintains Listing on the NASDAQ NEW YORK, July 16, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. ("Klotho" or the "Company") (NASDAQ: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases, today announced that it had received a notification letter from The NASDAQ Stock Market LLC confirming that the Company has regained compliance with the minimum $1.00 bid price under NASDAQ Listing Rule 5550(a)(2), and the minimum stockholders' equity threshold of $2.5 million under Listing Rule 5550(b)(1).

      7/16/25 6:00:00 AM ET
      $KLTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")

      NEW YORK, July 10, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company's novel secreted-Klotho (s-KL) promoter, gene and delivery system (KLTO-202, or s-KL-AAV.myo) for the treatment of ALS. The FDA grants Orphan Drug Designation to drugs and biologics that are intended for safe and effective treatment, diagnosis or prevention of rare diseas

      7/10/25 5:00:00 AM ET
      $KLTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS

      NEW YORK, June 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for clinical trials of KLTO-202, its investigational gene therapy for amyotrophic lateral sclerosis (ALS). A unique RNA splice variant of the human gene called alpha-Klotho has been licensed by the Company from the Autonomous University of Barcelona ("UAB") including patents, patent applications, research, knowhow and other intellectual properties for use in the development of advanced gene an

      6/30/25 2:00:00 AM ET
      $KLTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KLTO
    SEC Filings

    See more
    • Klotho Neurosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)

      7/18/25 5:10:37 PM ET
      $KLTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Klotho Neurosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)

      7/10/25 5:12:55 PM ET
      $KLTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by Klotho Neurosciences Inc.

      S-3 - Klotho Neurosciences, Inc. (0001907223) (Filer)

      7/3/25 6:56:05 PM ET
      $KLTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KLTO
    Leadership Updates

    Live Leadership Updates

    See more
    • Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences' Scientific Advisory Board

      NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer's and Parkinson's disease is proud to announce the appointment of Dr. Merit Cudkowicz, MD, MSc, to its Scientific Advisory Board (SAB). Dr. Cudkowicz is the Chair of Neurology at MGH, Director of the Sean M. Healey & AMG Center for ALS, and is the Julieanne Dorn Professor of Neurology at Harvard Medical School. A member of the National Academy of Medicine, Dr. Cudkowicz has been a leading clinician in promoting and devising more efficient methods for the development of thera

      12/9/24 11:00:00 AM ET
      $KLTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Former Merck USA President Joins Klotho Neurosciences' Board of Directors

      NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for neurodegenerative and age-related disorders, including ALS, Alzheimer's, and Parkinson's, today announced the appointment of Riad El-Dada, former US President of Merck, to its Board of Directors. With decades of leadership in the pharmaceutical industry, Mr. El-Dada brings extensive experience in product development, commercialization, and strategic partnerships. During his tenure as US President of Merck, he oversaw commercial teams across a dozen therapeutic areas, managing over $12 billion in revenue. Prior to that role, he ser

      12/3/24 11:00:00 AM ET
      $KLTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor

      NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ:KLTO), a leading biotechnology company focused on developing cell and gene therapies for aging and age-related diseases, is proud to announce the appointment of Dr. Makoto Kuro-o to its Scientific Advisory Board. Dr. Kuro-o, a distinguished Japanese physician-scientist, is widely recognized as the pioneer behind the discovery of the Klotho gene, often referred to as the "anti-aging gene." While conducting groundbreaking research at the National Institute of Neuroscience in Tokyo, Dr. Kuro-o and his team identified the Klotho gene while studying mice engineered to overexpress a gene linked to premature aging. Th

      10/23/24 6:00:00 AM ET
      $KLTO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care